PENTOTHAL
LOE ApproachingNDARECTALSUSPENSIONPriority Review
Approved
Sep 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PENTOTHAL is a rectal suspension small-molecule drug approved in 1959 by Abbott. Its specific indication and mechanism of action are not documented in available data, limiting commercial relevance assessment.
LOE Approaching
As a 65-year-old product approaching loss of exclusivity with minimal commercial data, team size is likely small and declining.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
The 1,624 linked jobs span diverse functions including R&D, engineering, and clinical operations, reflecting Abbott's broader organizational footprint rather than PENTOTHAL-specific demand. Working on this product offers limited career upside due to its approaching loss of exclusivity and minimal commercial momentum.
ScientistSr. Clinical Specialist
Worked on PENTOTHAL at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.